Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient.
about
Asenapine versus typical antipsychotics for schizophreniaAntipsychotics for people with persistent negative symptoms of schizophreniaF15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.Spotlight on brexpiprazole and its potential in the treatment of schizophrenia and as adjunctive therapy for the treatment of major depressionWhat does schizophrenia teach us about antipsychotics?Antipsychotic dosing: found in translationCurrent approaches to treatments for schizophrenia spectrum disorders, part I: an overview and medical treatmentsActivation of the canonical Wnt pathway by the antipsychotics haloperidol and clozapine involves dishevelled-3Disruption of conditioned reward association by typical and atypical antipsychotics.N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?Beyond dopamine: functional MRI predictors of responsiveness to cognitive behaviour therapy for psychosis.A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacyF15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. III. Activity in models of cognition and negative symptoms.Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data.Implications for atypical antipsychotics in the treatment of schizophrenia: neurocognition effects and a neuroprotective hypothesis.G protein-coupled receptor kinase-2 constitutively regulates D2 dopamine receptor expression and signaling independently of receptor phosphorylation.Orbitofrontal dopamine depletion upregulates caudate dopamine and alters behavior via changes in reinforcement sensitivity.Handwriting movement kinematics for quantifying extrapyramidal side effects in patients treated with atypical antipsychotics.Cannabinoids and Vanilloids in Schizophrenia: Neurophysiological Evidence and Directions for Basic Research.Schizophrenia: current concepts and approaches to patient careAntipsychotic dosing: how much but also how often?Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists.Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.Structural brain changes associated with antipsychotic treatment in schizophrenia as revealed by voxel-based morphometric MRI: an activation likelihood estimation meta-analysisDopamine and serotonin receptor binding and antipsychotic efficacy.Investigational drugs for schizophrenia targeting the dopamine receptor: phase II trials.Discovery, optimization, and characterization of novel D2 dopamine receptor selective antagonists.Targeting the dopamine receptor in schizophrenia: investigational drugs in Phase III trials.Antipsychotic drugs rapidly induce dopamine neuron depolarization block in a developmental rat model of schizophrenia.Understanding antipsychotic "atypicality": a clinical and pharmacological moving targetReview article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics.Novel antipsychotics in schizophrenia.The search for novel antipsychotics: pharmacological and molecular targets.Weight gain, schizophrenia and antipsychotics: new findings from animal model and pharmacogenomic studiesFrom antipsychotic to anti-schizophrenia drugs: role of animal models.Subtyping Schizophrenia by Treatment Response: Antipsychotic Development and the Central Role of Positive Symptoms.Towards a muscarinic hypothesis of schizophrenia.PET and SPECT imaging in psychiatric disorders.Cholinergic connectivity: it's implications for psychiatric disorders.Reinforcement and reversal learning in first-episode psychosis.
P2860
Q24197849-80E348C5-E706-46DC-B333-D6AACCB29875Q24239929-7024170F-3E43-40D2-ADBE-8BFCD4F9829AQ24564963-0E45157A-F707-4840-B8D6-60BB98B2FF5CQ26747833-87845D7E-D5E4-40D6-9655-65BB3F496754Q26823906-AF0164BA-EF53-4C8B-B75F-09DFB2E71C35Q26863343-5936D980-1D99-425F-9AE3-62971C11CD3AQ27003099-41B93777-ED49-47AA-8AA2-CE3300D16C3EQ28567705-13F3902E-A52D-4CBF-8870-B8D20000B81FQ30450317-6714D1AD-946D-48B8-B85F-5332B3091FF9Q30474021-7579D3B6-A97B-4F57-8E27-67759B903A84Q30483150-D5C32342-3305-467B-83A0-BE24CBC67D78Q30485065-534BE4A7-0685-4D7F-B582-14E4D407A7FDQ30494674-5E682F0F-367E-4262-883F-D636A4066BFFQ30747608-31C5841D-5A93-4D4E-BC8F-62AAFB8FFDCDQ30977943-B8A99128-0149-4E5B-A08F-49BA56D02458Q33553460-D51D0A08-225A-4EBB-9D95-F1926E575293Q33671729-80AA5A2F-71FC-482A-9A1A-E0C7785FABFDQ33811763-05B7940C-30CE-46D5-A8C4-82611E2A293FQ33819365-68DC6642-64D3-4773-BE6A-2E5F4AA557F7Q33932520-103306DE-C9FF-44F1-814C-1C0D14D9CAD6Q34023214-19A57DC9-EED0-40FF-A373-ACF77CDE405BQ34103173-86B884A2-71EA-4A33-BCFB-4933D9A26B80Q34274859-A68436DC-6FC7-4370-8FF4-BF1ADBD0C06AQ34393431-BDAC5091-9F94-4F4B-BE65-6CE1463444E0Q34605995-947626EA-A9A1-4211-BAB9-0D16258235BDQ34703195-D3F7CE6F-AF41-41E9-AA2D-D809AF1845EEQ35043389-9125D62C-6FC6-4D05-B9D9-169D56DCC04FQ35071909-922458EA-71D5-416B-86C8-FACE61D1F17FQ35197029-6C996E36-5EAC-47A4-AAF2-5D386B5D2A8DQ35200831-D09FA1C6-C33C-4F1B-A476-F638D4D3FC2BQ35661061-E9F0876D-CF9E-41D5-ABAB-65A73C5D9127Q35753453-31271CB9-C235-4394-A6E3-3ADD16A865E3Q35976379-3CD83F1A-FB17-49BD-8D13-9366E9D08C99Q36230583-4803F8AF-3933-4C9E-B91B-268680404E72Q36287726-88AFD121-D677-404D-88AA-B070741693B2Q36371727-A0334D70-0A17-4696-8CAE-0C18098214CCQ36673957-4A51811F-5F76-4F13-9262-F80DE097465CQ36811276-772B529B-472E-49E5-BCB8-0F861EC062CEQ36812599-FB838B65-71A7-4BA6-8706-70B05CD8C1C0Q36842935-0DFB943A-75BE-4B89-ABE9-DF614E95BFB3
P2860
Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient.
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Dopamine D(2) receptors and th ...... ry and may even be sufficient.
@ast
Dopamine D(2) receptors and th ...... ry and may even be sufficient.
@en
type
label
Dopamine D(2) receptors and th ...... ry and may even be sufficient.
@ast
Dopamine D(2) receptors and th ...... ry and may even be sufficient.
@en
prefLabel
Dopamine D(2) receptors and th ...... ry and may even be sufficient.
@ast
Dopamine D(2) receptors and th ...... ry and may even be sufficient.
@en
P1476
Dopamine D(2) receptors and th ...... ry and may even be sufficient.
@en
P2093
G Remington
P304
P356
10.1016/S0006-3223(01)01251-3
P407
P50
P577
2001-12-01T00:00:00Z